Does Effexor Affect Sex Drive? What the Venlafaxine Trials Actually Show

If you are asking about Effexor and sex drive, the short answer is yes: venlafaxine is one of the antidepressants most likely to lower desire, and in the largest study that asked people directly, 67.3% of those taking it reported a sexual problem. That puts it in the same pack as paroxetine and sertraline. Pristiq (desvenlafaxine) looks milder in its own trials, but those trials counted side effects in a different way. The depression or anxiety carries part of the drop, the effect tends to stay while you stay on the drug, and nobody can tell you what share of your own drop is the medicine.

Figures from Montejo et al. 2001 (PMID 11229449) and Clayton et al. 2015 (PMID 26230270). The first was open-label; the second pooled three trials after the fact.

Is it the Effexor, or is it me?

Depression and anxiety lower wanting on their own, and venlafaxine can add a layer on top. Kennedy and colleagues (2008) state it in their trial report: impaired sexual function goes with depression even before any drug. So when you ask "is it the Effexor, or is it me?", the fair answer is that it may be both, and no blood test or scan can split the two for one person. What the studies can show is how often the drug adds to the drop.

Clayton and colleagues (2002) surveyed 4,534 women and 1,763 men on a single antidepressant across 1,101 U.S. primary care clinics. SSRIs, mirtazapine and venlafaxine XR sat in the higher band, 36% to 43%, against 22% and 25% for the two forms of bupropion. Among people with no obvious other reason for sexual problems, prevalence ran from 7% to 30%, and the odds were 4 to 6 times higher on SSRIs or venlafaxine XR than on bupropion SR. The doctors consistently underestimated how often it happens. There was no placebo group, and venlafaxine XR's own percentage is not broken out.

How you are asked changes the count. Landen and colleagues (2005) questioned 119 people whose depression had not lifted on citalopram or paroxetine. When asked directly, 41% reported a sexual problem. Left to bring it up themselves, 6% did. Nobody in that study took venlafaxine, so read it as a lesson about asking. If no one raises sex at your appointments, your prescriber may never hear about it.

If you take venlafaxine for hot flushes, one 8-week trial in women without depression found no overall difference in sexual function scores against placebo, and low libido in menopause covers the rest of that picture. For the mood side, see depression and low libido and our guide to SSRIs and the libido drop.

How often venlafaxine does this, by the numbers

Montejo and colleagues (2001) give the plainest number. Their open-label study in Spain followed 1,022 adults who had normal sexual function before they started an antidepressant. Each was asked directly about desire, finishing, erections and satisfaction, and 59.1% reported a problem. On venlafaxine it was 67.3%, which is 37 of 55 people. About 40% of the whole group found the change hard to tolerate. Nobody was blinded, direct questions pull numbers up, and 55 people is a small group.

Serretti and Chiesa (2009) pooled studies that asked about sex directly, in people who had no problems beforehand. Ten drugs came out significantly worse than placebo, and venlafaxine was second in the order of impact, behind sertraline and ahead of citalopram, paroxetine and fluoxetine. Across those ten drugs, rates ran from 25.8% to 80.3%, a range that covers all ten and is no one drug's figure. Six drugs, bupropion and mirtazapine among them, showed no significant difference from placebo. The authors warn that including open-label studies and mixing different scales could weaken the ranking.

The largest placebo comparison in these sources comes from Kamp and colleagues (2024): 28 randomized trials and 6,253 adults with major depression. Serious adverse events were more common on venlafaxine, with a risk ratio of 2.66 (95% CI 1.67 to 4.25), and the authors say sexual dysfunction and loss of appetite drove most of that. Every result carried a high risk of bias and the certainty was rated very low. No trial ran past 12 weeks, so what happens over years of use is unknown.

Some studies put venlafaxine lower. Kennedy and colleagues (2000) rated 107 people with depression on moclobemide, paroxetine, sertraline or venlafaxine, before and after 8 or 14 weeks. Men reported more loss of drive and desire than women: 38% to 50% of men against 26% to 32% of women. Venlafaxine's rates tended to fall between the SSRIs and moclobemide. It was small, and its summary does not say how many took venlafaxine, so it does not overturn the larger studies.

Venlafaxine against the SSRIs and the other SNRIs

Montejo's per-drug counts let you line the drugs up. Citalopram reached 72.7% (48 of 66) and paroxetine 70.7% (147 of 208). Venlafaxine came next at 67.3%, then sertraline at 62.9% (100 of 159), fluvoxamine at 62.3% (48 of 77) and fluoxetine at 57.7% (161 of 279). Mirtazapine sat at 24.4%, nefazodone at 8%, amineptine at 6.9% and moclobemide at 3.9%. The authors grouped the SSRIs and venlafaxine together, at 58% to 73%.

That chart is one open-label study with direct questions, so every bar leans high. The venlafaxine bar rests on 55 people. Read it as "venlafaxine is in the high group" and hold the exact order loosely.

The only blinded head-to-head trial in these sources that measured desire on venlafaxine is Kennedy and colleagues (2008). They gave 276 adults with depression either agomelatine or venlafaxine XR, aimed at 150 milligrams a day, for 12 weeks. New sexual problems were significantly less common on agomelatine, and venlafaxine XR showed significantly more decline on the desire and finishing items of the Sex Effects Scale. Remission was similar, 73% and 66.9%, and 8.6% on venlafaxine XR stopped because of side effects against 2.2%. With no placebo arm, the trial cannot say how much of the decline came from the depression.

Among the other SNRIs, duloxetine has the clearest data. Delgado and colleagues (2005) pooled four 8-week double-blind trials: 736 people on duloxetine, 359 on paroxetine and 371 on placebo. New sexual problems were less common on duloxetine than on paroxetine, though both ran higher than placebo, and in a 26-week extension the three groups no longer differed. That was a post hoc pooling with no venlafaxine arm, so it describes a sister drug and says nothing direct about Effexor. What the duloxetine trials show goes further.

A wider network review keeps every ranking humble. Reichenpfader and colleagues (2014) pooled 63 studies and more than 26,000 people on newer antidepressants. Most pairs of drugs showed a similar risk, with wide credible intervals; bupropion came out lower than some, escitalopram and paroxetine higher than some. They rated the evidence low, and their summary does not place venlafaxine. For the SSRI side, see what the sertraline trials show and what the escitalopram trials show.

Pristiq (desvenlafaxine): the same drug family, measured differently

Pristiq (desvenlafaxine) belongs to the same family as venlafaxine, and its trial numbers look far smaller. Most of that gap comes from how the trials counted. Clayton and colleagues (2009) combined nine short placebo-controlled registration studies: 1,834 people on desvenlafaxine at 50 to 400 milligrams a day and 1,116 on placebo, for 8 weeks. The most common sexual side effect was erection problems in men, 7% against 1% on placebo, and trouble finishing in women, 1% against 0%. Those are side effects logged during a trial, and logged counts run far lower than answers to direct questions. The published summary does not say how anyone was asked about sex.

Measured with a questionnaire, the picture shifts. Clayton and colleagues (2015) pooled three randomized placebo-controlled trials and scored 1,562 people at week 8 on the Arizona Sexual Experiences Scale. At 50 milligrams, 54% scored in the dysfunction range, at 100 milligrams 47%, and on placebo 49%. The adjusted odds ratios, 1.205 (95% CI 0.928 to 1.564) and 1.129 (95% CI 0.795 to 1.604), both cross the line of no difference. So about half the people scored as having a problem whatever they took, which suggests the depression carries a large share in this group. The analysis was post hoc, and several authors listed drug-company affiliations.

Clayton and colleagues (2013) used the same scale in 422 employed adults over 12 weeks on 50 milligrams or placebo. Both groups changed by similar amounts: a mean difference of 0.90 in women (95% CI -0.38 to 2.18) and 0.07 in men (95% CI -1.59 to 1.74), neither significant. Men with no sexual problem at the start did have significantly more trouble finishing on desvenlafaxine. It was a post hoc look at one dose, and the published summary does not name a funder.

Montejo and colleagues (2019) followed 72 people on desvenlafaxine for three months, 45 of whom had switched to it because another antidepressant had flattened them. In the switched group, moderate or severe problems fell from 93.3% to 75.6%, and severe ones from 73% to 35%. The authors still wrote that desvenlafaxine is "not completely devoid of sexual adverse effects." There was no control group, so some of the change could be the depression lifting.

None of these sources asked the Spanish study's direct questions about desvenlafaxine, so its 54% and venlafaxine's 67.3% come from different methods and cannot be ranked.

What the switch and add-on trials found

Waiting it out has little evidence behind it, which is hard to hear when you just want to feel normal again. Jacobsen and colleagues (2015) opened their trial report by stating that the sexual side effects of SSRIs and SNRIs do not resolve in most people. Landen and colleagues (2005) found the problem tracked the length of the depressive episode, with no link to dose, blood level or time on the drug. Neither study included anyone on venlafaxine, and every venlafaxine trial in the 2024 review stopped by 12 weeks, so the long view on Effexor itself is thin. If your numbers are fine and you still feel flat, numbers fine, still flat is worth a read.

Taylor and colleagues (2013) ran the Cochrane review of strategies for antidepressant-related sexual problems: 23 trials and 1,886 people, with most add-ons tested in a single study. In men, sildenafil (three studies, 255 men) and tadalafil (one study, 54 men) improved erection scores against placebo. Bupropion 150 milligrams twice daily beat placebo on rating scales (SMD 1.60, 95% CI 1.40 to 1.81, three studies), while once daily made no significant difference (RR 0.62, 95% CI 0.09 to 4.41). The other add-ons failed to show a significant improvement. The review found no randomized trials of switching to a currently available lower-side-effect drug, of drug holidays or of psychological approaches, and it called the evidence "rather limited."

On switching, the best trial in this set compared two drugs after an SSRI. Jacobsen and colleagues (2015) moved adults whose depression was well controlled, but who had sexual side effects on citalopram, paroxetine or sertraline, to vortioxetine (225 people) or escitalopram (222 people) for 8 weeks. Scores on the CSFQ-14 improved by 8.8 on vortioxetine against 6.6 on escitalopram (P = 0.013). Nobody in it came off venlafaxine, so it only suggests a switch is worth raising with your prescriber. For the full bupropion picture, see what the bupropion trials show.

Effexor and sex drive: what each study can tell you

Some of these studies rank drugs by how many people report a change when asked. Others test Pristiq against placebo, or test add-ons after the drop has happened. Each answers its own question and says little about the others, so the venlafaxine and desvenlafaxine numbers stay in separate rows.

What to bring to your prescriber

Take this list, in this order.

1. When the change started. Write down the date you began venlafaxine or desvenlafaxine, every dose change since, and when you first noticed the drop. If desire was already low before the drug, say so, because depression lowers it too.
2. Ask to be asked. In one small study, 41% reported a sexual problem when asked directly and 6% mentioned it unprompted. Raising it yourself puts it on the record.
3. What you are taking it for. Depression, anxiety and hot flushes are different reasons for the same drug, and the trade-off your prescriber weighs is different for each.
4. Whether waiting is a plan. The evidence says the side effect usually stays while the drug stays, and no venlafaxine trial in the 2024 review ran past 12 weeks.
5. The options with a trial signal. Bupropion 150 milligrams twice daily, and for men the erection drugs. The 2013 Cochrane review found no randomized trial of switching to a currently available lower-side-effect drug; one 2015 trial has since tested a switch away from an SSRI. Only your prescriber should change the plan.
6. Any supplement, bottle in hand. NUUD does nothing for depression, anxiety, hot flushes or medication side effects, and no interaction studies exist for this formula. Bring the label and ask.

"I've tried everything"

If you have already been through the add-ons, the honest count is short. Bupropion 150 milligrams twice daily showed a signal in trials. For men, sildenafil and tadalafil did. Once-daily bupropion did not, and the rest of the add-ons in the Cochrane review failed to show a significant improvement. So "tried everything" often means you tried the things that were never likely to clear the bar. No trial here tested the things that shape desire for most people anyway, like sleep, the load you carry and how things are with your partner. Look at those before you decide nothing works. When you want to want it again, libido after stopping antidepressants covers the coming-off question, and what HSDD means explains the clinical term for low desire and who it fits.

The everyday levers, and where a botanical fits

Start with who this section is not for. Blood-pressure medication, heart conditions, kidney and lung problems are exactly what NUUD's own label warns about: avoid use if you are on blood pressure medication, have cardiovascular, renal, or pulmonary conditions, or if you are sensitive to any of the ingredients. Pristiq's own registration trials recorded small but statistically significant blood-pressure changes at every dose. For many readers of this article, that label line is the answer. Talk to your prescriber first and bring the label.

A few ordinary things move desire in most people, and the free ones do more work than the internet admits.

• Sleep, in quantity and quality, since fatigue and broken nights feed a flat drive. Sleep, libido and testosterone covers that.
• Movement you can keep up. Exercise and libido covers the wider picture.
• Care for the depression or the anxiety, since the illness carries part of the drop and your prescriber can adjust that plan directly.
• Time and safety, with a partner or on your own, with nothing expected at the end.
• A botanical supplement, if you want one, as the smallest lever on the list.

NUUD is a botanical supplement built around desire in general; it does nothing for depression, anxiety, hot flushes, or the side effects of Effexor, Pristiq or any antidepressant, and it has no role in managing any medical condition. The formula is anchored by the NUUD Mushroom Complex™, with Muira Puama, Boiled Rehmannia Root, Tribulus Terrestris, and Piper Nigrum for absorption, and it takes roughly 30 to 60 minutes to kick in. If you take blood-pressure medication or have a heart, kidney or lung condition, the label says no, and your prescriber decides the rest. If your prescriber has read that label and has no objection, that is what our women's libido gummies are for. There is a men's version.

Nothing is wrong with you

Your prescriber chose venlafaxine knowing where it sits. In the Spanish study, 67.3% of the people on it reported a sexual change when asked, and in the 2009 ranking only sertraline came out ahead of it. That is a known cost of the medicine, weighed against what it does for your mood, and it says nothing about you as a partner. Depression and anxiety flatten wanting on their own too, underneath the drug the whole time. If you want to want it again and you just want to feel normal again, both are fair things to ask for out loud, and the list above is where to start.

Keep reading

• Does Cymbalta affect sex drive?
• SSRIs and the libido drop: what helps
• Does Zoloft affect sex drive?
• Does Lexapro affect sex drive?
• Does Wellbutrin affect sex drive?
• Antidepressants and low libido

Frequently asked questions

Does Effexor lower sex drive?
Often, yes. In a Spanish study of 1,022 people asked directly, 67.3% of the 55 on venlafaxine reported a sexual problem, close to paroxetine and sertraline. A 2009 meta-analysis ranked it second of ten antidepressants for new sexual problems, behind sertraline. The Spanish study was open-label with direct questions, so its figures lean high, and depression lowers desire by itself, so part of any drop can be the illness. Nobody can say for one person how much of it is the drug.

Is Pristiq better than Effexor for sex drive?
The trials cannot settle it, because the two drugs were counted differently. Pristiq's registration trials logged side effects, such as erection problems in 7% of men against 1% on placebo. A pooled questionnaire analysis of 1,562 people found 54% on 50 milligrams and 49% on placebo in the dysfunction range, with no significant difference. That analysis was post hoc, and several authors listed drug-company affiliations. Venlafaxine's 67.3% came from a separate open-label study that asked directly, so the numbers cannot be set side by side.

Will my sex drive come back if I stop Effexor?
Nobody can promise that for one person, and none of the studies here measured desire after stopping venlafaxine. What they do show is that the side effect tends to stay while you stay on the drug: a 2015 trial report said the sexual side effects of SSRIs and SNRIs do not resolve in most people, and the venlafaxine trials in a 2024 review lasted 12 weeks at most. Stopping is a decision for you and your prescriber together, never one to make alone, because coming off needs a plan.

Is Effexor worse than Zoloft or Lexapro for sex drive?
It sits in the same high group as Zoloft (sertraline), and the Lexapro (escitalopram) evidence points both ways. In the Spanish study, venlafaxine came in at 67.3% and sertraline at 62.9%, a small gap in an open-label study. The 2009 meta-analysis ranked sertraline first, venlafaxine second and escitalopram ninth of ten. A 2014 network review of 63 studies found most drugs at a similar risk, with wide intervals, and escitalopram higher than some others. No single ranking settles which is worse for you.

Can I take a botanical supplement with Effexor?
Only after your prescriber has seen the label. NUUD's caution reads: avoid use if you are on blood pressure medication, have cardiovascular, renal, or pulmonary conditions, or if you are sensitive to any of the ingredients. NUUD does nothing for depression, anxiety, hot flushes, or the side effects of Effexor, Pristiq or any antidepressant, and no interaction studies exist for this formula with venlafaxine or desvenlafaxine. Bring the bottle to your next appointment and let your prescriber decide with the label in front of them.

References

1. Montejo AL, Llorca G, Izquierdo JA, Rico-Villademoros F. Incidence of sexual dysfunction associated with antidepressant agents: a prospective multicenter study of 1022 outpatients. Spanish Working Group for the Study of Psychotropic-Related Sexual Dysfunction. The Journal of clinical psychiatry. 2001;62 Suppl 3:10-21. https://pubmed.ncbi.nlm.nih.gov/11229449/
2. Serretti A, Chiesa A. Treatment-emergent sexual dysfunction related to antidepressants: a meta-analysis. Journal of clinical psychopharmacology. 2009;29(3):259-66. https://pubmed.ncbi.nlm.nih.gov/19440080/
3. Clayton AH, Pradko JF, Croft HA, Montano CB, Leadbetter RA, Bolden-Watson C, et al. Prevalence of sexual dysfunction among newer antidepressants. The Journal of clinical psychiatry. 2002;63(4):357-66. https://pubmed.ncbi.nlm.nih.gov/12000211/
4. Kennedy SH, Eisfeld BS, Dickens SE, Bacchiochi JR, Bagby RM. Antidepressant-induced sexual dysfunction during treatment with moclobemide, paroxetine, sertraline, and venlafaxine. The Journal of clinical psychiatry. 2000;61(4):276-81. https://pubmed.ncbi.nlm.nih.gov/10830148/
5. Kamp CB, Petersen JJ, Faltermeier P, Juul S, Siddiqui F, Moncrieff J, et al. The risks of adverse events with venlafaxine for adults with major depressive disorder: a systematic review of randomised clinical trials with meta-analysis and Trial Sequential Analysis. Epidemiology and psychiatric sciences. 2024;33:e51. https://pubmed.ncbi.nlm.nih.gov/39440379/
6. Kennedy SH, Rizvi S, Fulton K, Rasmussen J. A double-blind comparison of sexual functioning, antidepressant efficacy, and tolerability between agomelatine and venlafaxine XR. Journal of clinical psychopharmacology. 2008;28(3):329-33. https://pubmed.ncbi.nlm.nih.gov/18480691/
7. Reichenpfader U, Gartlehner G, Morgan LC, Greenblatt A, Nussbaumer B, Hansen RA, et al. Sexual dysfunction associated with second-generation antidepressants in patients with major depressive disorder: results from a systematic review with network meta-analysis. Drug safety. 2014;37(1):19-31. https://pubmed.ncbi.nlm.nih.gov/24338044/
8. Delgado PL, Brannan SK, Mallinckrodt CH, Tran PV, McNamara RK, Wang F, et al. Sexual functioning assessed in 4 double-blind placebo- and paroxetine-controlled trials of duloxetine for major depressive disorder. The Journal of clinical psychiatry. 2005;66(6):686-92. https://pubmed.ncbi.nlm.nih.gov/15960560/
9. Clayton AH, Kornstein SG, Rosas G, Guico-Pabia C, Tourian KA. An integrated analysis of the safety and tolerability of desvenlafaxine compared with placebo in the treatment of major depressive disorder. CNS spectrums. 2009;14(4):183-95. https://pubmed.ncbi.nlm.nih.gov/19407730/
10. Clayton AH, Reddy S, Focht K, Musgnung J, Fayyad R. An evaluation of sexual functioning in employed outpatients with major depressive disorder treated with desvenlafaxine 50 mg or placebo. The journal of sexual medicine. 2013;10(3):768-76. https://pubmed.ncbi.nlm.nih.gov/22905811/
11. Clayton AH, Hwang E, Kornstein SG, Tourian KA, Cheng RF, Abraham L, et al. Effects of 50 and 100 mg desvenlafaxine versus placebo on sexual function in patients with major depressive disorder: a meta-analysis. International clinical psychopharmacology. 2015;30(6):307-15. https://pubmed.ncbi.nlm.nih.gov/26230270/
12. Montejo AL, Becker J, Bueno G, Fernández-Ovejero R, Gallego MT, González N, et al. Frequency of Sexual Dysfunction in Patients Treated with Desvenlafaxine: A Prospective Naturalistic Study. Journal of clinical medicine. 2019;8(5):719. https://pubmed.ncbi.nlm.nih.gov/31117203/
13. Reed SD, Mitchell CM, Joffe H, Cohen L, Shifren JL, Newton KM, et al. Sexual function in women on estradiol or venlafaxine for hot flushes: a randomized controlled trial. Obstetrics and gynecology. 2014;124(2 Pt 1):233-241. https://pubmed.ncbi.nlm.nih.gov/25004335/
14. Taylor MJ, Rudkin L, Bullemor-Day P, Lubin J, Chukwujekwu C, Hawton K. Strategies for managing sexual dysfunction induced by antidepressant medication. The Cochrane database of systematic reviews. 2013;2013(5):CD003382. https://pubmed.ncbi.nlm.nih.gov/23728643/
15. Jacobsen PL, Mahableshwarkar AR, Chen Y, Chrones L, Clayton AH. Effect of Vortioxetine vs. Escitalopram on Sexual Functioning in Adults with Well-Treated Major Depressive Disorder Experiencing SSRI-Induced Sexual Dysfunction. The journal of sexual medicine. 2015;12(10):2036-48. https://pubmed.ncbi.nlm.nih.gov/26331383/
16. Landén M, Högberg P, Thase ME. Incidence of sexual side effects in refractory depression during treatment with citalopram or paroxetine. The Journal of clinical psychiatry. 2005;66(1):100-6. https://pubmed.ncbi.nlm.nih.gov/15669895/

This article is for general education and is not medical advice. Depression and anxiety are medical conditions that only a licensed clinician can diagnose and manage, and Effexor (venlafaxine) and Pristiq (desvenlafaxine) are prescription medicines. NUUD is a botanical supplement and has no role in diagnosing, treating, curing, or preventing depression, anxiety, the side effects of any medication, or any other disease, and these statements have not been evaluated by the Food and Drug Administration. Talk with your doctor before starting any new supplement, and do not stop or change your medication without your doctor.